Publications: Our research

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without human immunodeficiency virus type 1 infection

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4+ and CD8+ T cell responses

Current Protocol for Phase 3 Clinical Trial of NVX-CoV2373 in the U.S. and Mexico

NVX-CoV2373 Vaccine for COVID-19

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

In-depth Analytical Characterization and Structural Modeling of Novavax RSV F Nanoparticle Vaccine

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States

Immunogenicity and Safety Following a Homologous Boosater Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial